Needham analyst Mike Matson raised his price target on Merit Medical to $67 and kept his Buy rating after its better than expected Q2 results. The analyst notes that organic revenue growth has improved relative to Q1 despite the difficult comps and gross margins grew 60bps, even though he expected a higher rate of expansion. Matson anticipates Merit Medical to further improve in the second half of 2018 as comps ease and continued product shortage at Terumo benefits the company. The analyst also cites the positive impact from the "recent accretive acquisitions, manufacturing efficiencies, and higher margin product launches".